Filing summary
Entity and period: The supplied filing is Spatializer Audio Laboratories, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015. This does not match the request metadata naming Enveric Biosciences, Inc.; investors should verify the issuer before relying on this summary.
Business context and financial position
The company reported that it discontinued its operating business in 2007 and is now a shell company seeking an acquisition or merger partner. It reported no operating activities during the quarter.
| Metric | Q1 2015 / March 31, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2014, as stated in MD&A |
| General and administrative expense | $2,300 | $7,584 in Q1 2014 |
| Operating loss | $2,300 | $7,584 in Q1 2014 |
| Net loss | $2,575 | $7,867 in Q1 2014 |
| Cash and cash equivalents | $3,898 | $5,085 at December 31, 2014 |
| Current liabilities | $10,344 | $8,956 at December 31, 2014 |
| Stockholders’ deficit | $6,446 | $3,871 at December 31, 2014 |
| Net cash used in operating activities | $1,187 | $27,779 in Q1 2014 |
No revenue or gross margin was reported, so operating margins are not meaningful. The filing reports no debt at March 31; a $50,000 promissory note was issued after quarter-end. Cash at quarter-end was below current liabilities. The filing does not provide a clear current ratio or other liquidity measure.
Material changes and unusual items
- Net loss narrowed from $7,867 to $2,575, and general and administrative expense declined, which management attributed to lower legal fees.
- Operating cash use was lower than in Q1 2014. The cash-flow statement reports no financing proceeds in Q1 2015; Q1 2014 included $50,000 from a common-stock issuance.
- After quarter-end, on April 17, the company issued a $50,000 note to Lone Star Value Investors, LP, bearing 10% annual interest and due on or before April 30, 2020. Proceeds were intended for legal and operating expenses.
- On April 20, the board received discretionary authority to implement a reverse split of up to 1-for-18, reduce authorized common shares to 100 million, change the company name to AMERI Holdings, Inc., and adopt a 2015 equity incentive plan. These actions were authorized, not stated as completed.
Outlook, risks, and contingencies
Management stated that the company is seeking an acquisition or merger partner but gave no operating or financial guidance. It warned that it may be unable to complete a transaction or maintain sufficient liquidity, and could be forced to liquidate or seek bankruptcy protection. The financial statements include a going-concern uncertainty and no adjustments for a possible inability to continue as a going concern. Management identified working capital, transaction execution, economic conditions, and retention of key personnel among relevant risks. No legal proceedings were reported. Tax-loss carryforwards may be limited and management believes they are unlikely to be fully realized.
Key facts for investors to verify
- Confirm that this Spatializer Audio Laboratories filing—not an Enveric Biosciences filing—is the intended document.
- Verify the status and terms of the post-quarter-end $50,000 note, including its related-party nature, use of proceeds, and repayment obligations.
- Check whether the proposed reverse split, name change, authorized-share amendment, and equity incentive plan were subsequently implemented, and review the referenced May 2015 Schedule 14C.
- Assess the company’s available liquidity and ability to fund ongoing expenses while pursuing a transaction.